HAMP and heart failure: In patients with heart failure with reduced ejection fraction, dapagliflozin decreased circulating transferrin saturation (TSAT), ferritin and hepcidin, and increased total iron binding capacity (TIBC), suggesting that SGLT2 inhibition might increase iron use by addressing hepcidin-induced functional iron blockade [12].